A Novel, Circulating Tumor Cell Enrichment Method Reduces ARv7 False Positivity in Patients with Castration-Resistant Prostate Cancer.
AR-V7
Abiraterone
Androgen receptors
Cabazitaxel
Docetaxel
Enzalutamide
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
11 Mar 2020
11 Mar 2020
Historique:
received:
19
02
2020
revised:
08
03
2020
accepted:
09
03
2020
entrez:
15
3
2020
pubmed:
15
3
2020
medline:
15
3
2020
Statut:
epublish
Résumé
The AR-V7 splice variant is a cause of castration-resistant prostate cancer (CRPC). However, testing for the presence of AR-V7 by real-time polymerase chain reaction (RT-PCR) shows AR-V7 positivity in healthy individuals. We hypothesized that the positivity reflects contamination by hematopoietic cells. We tried a novel circulating tumor cell (CTC) enrichment instrument, using Celsee, to clear hematopoietic cells. We tested whole blood or Celsee-enriched samples for AR-V7 by RT-PCR, and included samples from 41 CRPC patients undergoing sequential therapy. We evaluated the associations between AR-V7 status and clinical factors. We evaluated factors affecting AR-V7 positivity. AR-V7 positivity was lower in Celsee-enriched than in whole blood specimens. AR-V7 and clinical factors did not predict the therapy effectiveness. We found no significant differences in the effectiveness of enzalutamide/abiraterone (Enz/Abi) upon AR-V7 evaluation. All AR-V7 positive patients had resistance to Enz/Abi. Docetaxel (DTX), cabazitaxel (CBZ), and Radium223 treatment showed no significant difference in the treatment effectiveness, regardless of AR-V7 presence. AR-V7 was more frequently positive than Extent of disease (EOD) 2 in cases with bone metastases. Celsee CTC enrichment suppresses AR-V7 false positivity. All AR-V7 positive patients presented resistance to Enz/Abi. DTX, CBZ, and Radium223 were effective and remain treatment options. AR-V7 positivity should progressively appear in patients with advanced bone metastases.
Sections du résumé
BACKGROUND
BACKGROUND
The AR-V7 splice variant is a cause of castration-resistant prostate cancer (CRPC). However, testing for the presence of AR-V7 by real-time polymerase chain reaction (RT-PCR) shows AR-V7 positivity in healthy individuals. We hypothesized that the positivity reflects contamination by hematopoietic cells. We tried a novel circulating tumor cell (CTC) enrichment instrument, using Celsee, to clear hematopoietic cells.
METHODS
METHODS
We tested whole blood or Celsee-enriched samples for AR-V7 by RT-PCR, and included samples from 41 CRPC patients undergoing sequential therapy. We evaluated the associations between AR-V7 status and clinical factors. We evaluated factors affecting AR-V7 positivity.
RESULTS
RESULTS
AR-V7 positivity was lower in Celsee-enriched than in whole blood specimens. AR-V7 and clinical factors did not predict the therapy effectiveness. We found no significant differences in the effectiveness of enzalutamide/abiraterone (Enz/Abi) upon AR-V7 evaluation. All AR-V7 positive patients had resistance to Enz/Abi. Docetaxel (DTX), cabazitaxel (CBZ), and Radium223 treatment showed no significant difference in the treatment effectiveness, regardless of AR-V7 presence. AR-V7 was more frequently positive than Extent of disease (EOD) 2 in cases with bone metastases.
CONCLUSION
CONCLUSIONS
Celsee CTC enrichment suppresses AR-V7 false positivity. All AR-V7 positive patients presented resistance to Enz/Abi. DTX, CBZ, and Radium223 were effective and remain treatment options. AR-V7 positivity should progressively appear in patients with advanced bone metastases.
Identifiants
pubmed: 32168745
pii: diagnostics10030151
doi: 10.3390/diagnostics10030151
pmc: PMC7151149
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
PLoS One. 2016 Jan 25;11(1):e0147400
pubmed: 26808060
J Clin Oncol. 2016 Apr 20;34(12):1402-18
pubmed: 26903579
Nat Rev Cancer. 2014 Sep;14(9):623-31
pubmed: 25154812
Eur Urol. 2017 Jan;71(1):1-3
pubmed: 27471164
Ann Oncol. 2015 Sep;26(9):1859-65
pubmed: 26117829
Transl Androl Urol. 2015 Jun;4(3):365-80
pubmed: 26814148
N Engl J Med. 2014 Sep 11;371(11):1028-38
pubmed: 25184630
Br J Cancer. 2004 Jun 14;90(12):2317-25
pubmed: 15150570
J Clin Oncol. 2008 Oct 1;26(28):4563-71
pubmed: 18645193
Cancer Res. 2012 Jul 15;72(14):3457-62
pubmed: 22710436
JAMA Oncol. 2015 Aug;1(5):582-91
pubmed: 26181238
Eur Urol. 2015 Dec;68(6):939-45
pubmed: 26188394
J Urol. 2017 Jan;197(1):135-142
pubmed: 27436429
Clin Cancer Res. 2017 Feb 1;23(3):726-734
pubmed: 27489290
Eur Urol. 2016 Oct;70(4):599-608
pubmed: 27117751
Lancet. 2010 Apr 24;375(9724):1437-46
pubmed: 20398925
Cancer Res. 2009 Jan 1;69(1):16-22
pubmed: 19117982
Medicine (Baltimore). 2019 May;98(19):e15608
pubmed: 31083254
J Clin Oncol. 2019 May 1;37(13):1120-1129
pubmed: 30865549
Res Rep Urol. 2016 Jan 28;8:21-5
pubmed: 26870716
Cells. 2020 Jan 14;9(1):
pubmed: 31947623
Science. 2009 May 8;324(5928):787-90
pubmed: 19359544
Int J Oncol. 2014 Jun;44(6):1870-8
pubmed: 24676558